G&S Capital LLC Cel Sci Corp Transaction History

G&S Capital LLC

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2020 Jul 24, 2020	SELL	$9.75 - $17.6 $975 - $1,760	-100 Closed	0 $0
Q1 2020 Apr 23, 2020	BUY	$7.54 - $17.05 $754 - $1,705	100 New	100 $1,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of G&S Capital LLC, based on Form 13F filings with the SEC.

Stay updated on G&S Capital LLC with notifications on news.